David Braley Centre for Antibiotic Discovery, M.G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Nat Microbiol. 2019 Nov;4(11):1862-1871. doi: 10.1038/s41564-019-0531-5. Epub 2019 Aug 12.
Glycopeptide antibiotics are produced by Actinobacteria through biosynthetic gene clusters that include genes supporting their regulation, synthesis, export and resistance. The chemical and biosynthetic diversities of glycopeptides are the product of an intricate evolutionary history. Extracting this history from genome sequences is difficult as conservation of the individual components of these gene clusters is variable and each component can have a different trajectory. We show that glycopeptide biosynthesis and resistance in Actinobacteria maps to approximately 150-400 million years ago. Phylogenetic reconciliation reveals that the precursors of glycopeptide biosynthesis are far older than other components, implying that these clusters arose from a pre-existing pool of genes. We find that resistance appeared contemporaneously with biosynthetic genes, raising the possibility that the mechanism of action of glycopeptides was a driver of diversification in these gene clusters. Our results put antibiotic biosynthesis and resistance into an evolutionary context and can guide the future discovery of compounds possessing new mechanisms of action, which are especially needed as the usefulness of the antibiotics available at present is imperilled by human activity.
糖肽类抗生素是放线菌通过生物合成基因簇产生的,这些基因簇包括支持其调控、合成、输出和抗性的基因。糖肽的化学和生物合成多样性是其复杂进化历史的产物。从基因组序列中提取这些历史信息很困难,因为这些基因簇的各个组成部分的保守性是可变的,每个组成部分都可能有不同的轨迹。我们表明,放线菌中的糖肽生物合成和抗性可追溯到大约 1.5 亿至 4 亿年前。系统发育协调揭示了糖肽生物合成的前体远比其他成分古老,这意味着这些簇是由预先存在的基因库产生的。我们发现,抗性与生物合成基因同时出现,这增加了糖肽作用机制是这些基因簇多样化的驱动力的可能性。我们的研究结果将抗生素生物合成和抗性置于进化背景下,并可以指导未来具有新作用机制的化合物的发现,这在当前可用抗生素的有效性因人类活动而受到威胁的情况下尤其需要。